Eisenmenger Complex Management Market

Eisenmenger Complex Management Market Snapshot (2023 to 2033)

The global Eisenmenger complex management market is expected to surpass an impressive valuation of USD 7.7 Billion in 2023 and is projected to reach USD 12.9 Billion by 2033, trailing at a CAGR of 5.3%

The increase in the number of patients suffering from mild congenital heart diseases and the growing focus on research and development activities related to the development of advanced drugs are factors anticipated to drive the growth of the global Eisenmenger syndrome treatment market. About 1 in 4 babies with congenital heart diseases have critical CHDs. Infants with the critical disease generally need surgery or other procedures in their first year of life.

Rising investment by major players for the development of innovative solutions and high spending on healthcare infrastructure development are factors anticipated to create new prospects for players operating in the Eisenmenger syndrome treatment market over the forecast period. In addition, growing partnership and agreements between players in order to improve the business presence is expected to support the revenue growth of the target market.

Report Attribute	Details
Expected Market Value (2023)	USD 7.7Billion
Anticipated Forecast Value (2033)	USD 12.9 Billion
Projected Growth Rate (2023 to 2033)	CAGR 5.3%

2018 to 2022 Eisenmenger Complex Management Demand Analysis vs. Forecast 2023 to 2033

The market for Eisenmenger complex treatment market was worth USD 6.2 Billion in 2018, growing at a CAGR of 4.52% during the historical period. Continuous requirement of medication supports the growth of the Eisenmenger Syndrome Treatment Market.

Eisenmenger Syndrome is a chronic disease and requires medication to be taken for a long period of time. The incidence and prevalence of Eisenmenger syndrome have not been properly defined due to the highly specific nature of the condition. However, according to National Center for Biotechnology Information (NCBI), 2010, an estimated 8% of patients with congenital heart disease are expected to develop Eisenmenger syndrome. Though technological and healthcare advancements have made it possible to correct congenital heart defects, the responses have been poor in the case of patients suffering from Eisenmenger syndrome.

Also, the presence of disease-targeting therapies such as Sildenafil and Bosentan is expected to boost market growth during the forecast period, due to the unavailability of alternative options. Furthermore, combination therapies are also expected to boost market growth over the forecast period. After a comprehensive analysis of the above-mentioned growth factors, the market for Eisenmenger syndrome treatment is projected to grow at a 5.3% CAGR while reaching a market valuation of USD 12.9 billion by end of the forecast period.

Which are Some Prominent Drivers of the Eisenmenger Complex Management Market?

Increasing clinical trials for product development to drive market growth

Major players are investing highly in developing products such as blood thinning agents and endothelin receptor antagonists in order to treat the problems. Increasing clinical trials related to the development of new products is expected to augment the growth of the target market. In 2021, The USA. Food and Drug Administration approved “Pradaxa” a blood thinning agent. The approval of Pradaxa is expected to help pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots.

The presence of disease-targeting therapies such as Sildenafil and Bosentan has boosted the market growth over the past years and the trend is expected to remain the same, owing to the unavailability of alternative options. Moreover, combination therapies are also expected to boost the growth of the market over the forecast period. European Society of Cardiology Consensus Guidelines, 2015, suggests the use of combination therapy (Sildenafil + Bosentan, and others) in the management of pulmonary hypertension. These factors are expected to boost the growth of the market over the forecast period.

The government of developed and developing countries is spending high on the development of the healthcare sector. Their approach towards providing advanced care to patients along with better diagnostic facilities is gaining traction. Diagnosis tests such as blood tests, electrocardiograms (ECG), and chest X-rays are gaining attraction among consumers. Awareness related to these testing is increasing and is widely adopted by consumers.

What are the Challenges Projected to be Faced by the Market?

High costs of equipment and dearth of infrastructure restraining growth

Factors such as a lack of developed infrastructure and complex regulations by the government for product approval are anticipated to restrain the growth of the global Eisenmenger syndrome treatment market. In addition, the high cost associated with the development of equipment is expected to challenge the growth of this market.

Region-Wise Insights

What is the growth outlook in North America?

North America dominates the market with a significant market share

The market in North America is expected to account for 48.7% market share with a CAGR of 5.1% during the forecast period. The growth is attributable to a high patient pool suffering from chronic diseases. The presence of many players operating in the country and introducing new solutions are factors expected to augment the regional market growth. In addition, increasing acquisition activities by major players in order to enhance the business and enhance the customer base is expected to support the growth of the Eisenmenger syndrome treatment market.

What are the growth prospects in South Asia?

South Asia will propel growth by witnessing the fastest CAGR

The market in South Asia is expected to witness the fastest compound annual growth rate of 5.5 % during the forecast period. Factors responsible for growth in this region are increasing government spending on the healthcare sector, favorable business policies by the government, and the emergence of small and mid-size players with enhanced solutions. These factors are expected to support the growth of Eisenmenger's complex management market.

Category wise Insights

By drug type, which segment will possess the maximum share?

Endothelin receptor antagonist to account for the dominant share

This segment is anticipated to dominate the market while capturing a 48.1% segment share in 2023. It is estimated to reflect a CAGR of 6.1% during the forecast period. The growth is attributed to favorable long-term and short-term outcomes in trials with orally active dual endothelin receptor antagonist bosentan in patients with Eisenmenger's syndrome. Furthermore, the safety and efficacy of these drugs in correcting the Eisenmenger syndrome are also driving the growth of this segment. Furthermore, increasing adoption of Endothelin receptor antagonist as a targeted therapy to dilate blood vessels, delay the progression of pulmonary arterial hypertension, and reverse the damage to the lungs and heart are set to fuel this segment over the forthcoming years.

Which is the leading distribution channel in Eisenmenger complex management market?

Hospital pharmacies rule the market with the maximum share

In terms of distribution channels, the hospital pharmacies segment is projected to remain at the forefront in the assessment period. It is estimated to account for a market share of 65% by end of the forecast period. The growth is attributable to the increasing patient visits to hospitals for the treatment of Eisenmenger syndrome.

In addition, the increasing sales of prescribed drugs for the treatment of this disorder from hospital pharmacies are anticipated to support the growth of this segment. Besides, many government agencies are likely to set up awareness campaigns in hospitals to educate the general public about this condition and the drugs available for treatment. This factor is also expected to boost the growth of this segment in the near future.

Start-ups in Eisenmenger Complex Management Market

• Founded in 2015, Morphogen-IX is a Cambridge, United Kingdom-based start-up that is developing a new treatment for pulmonary arterial hypertension (PAH). Its leading candidate can directly target the major pathway implicated in human genetic studies (BMP9 and BMP10) which are small molecule-based receptors. This company was granted funding of USD 25.3 million from Medicxi, Cambridge Innovation Capital, Index Ventures, Cambridge Enterprise, and 2 others. The latest funding round was held in December 2018.
• Founded in 2012, ‘1 Drop diagnostics’ is a Neuchatel, Switzerland-based start-up that provides finger-prick point-of-care diagnostic solutions. The proprietary technology uses a combination of lab-on-chip microfluidic technology that enables biomarker testing to occur using very small volumes of blood, and advanced photonics to easily detect fluorescence due to the immunoassays. The first application is cardiovascular health, using biomarkers such as NT-proBNP, D-Dimer, Troponin, and C-reactive protein. It was granted funding of USD 8 million from Christian Wildmoser, Hans-Peter Strebel, Beat Schillig, and 9 Other Investors.

Market Competition

The global Eisenmenger syndrome treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are Actelion Pharmaceuticals Ltd, Gilead Sciences, Inc., Pfizer, Inc, Teva Pharmaceutical Industries Ltd, AstraZeneca plc., Novartis AG, Merck and Co., Inc., GlaxoSmithKline plc., Mylan N.V, Bayer AG.

Some recent developments in this industry are:

• In July 2022, Cereno Scientific announced that the first patient had been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1.
• In June 2022, Gossamer Bio, Inc. declared the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
• In December 2021, Aerovate Therapeutics, a clinical-stage biopharmaceutical company based in the United States, started the Phase 2b/3 clinical trial for testing imatinib, its experimental inhaled formulation in people with Eisenmenger syndrome. The trial is set to help the company in achieving the goal of enhancing the lives of patients suffering from rare cardiovascular diseases. This test will evaluate the ability of AV-101 to resist blood flow in the blood vessels of the lungs.
• In December 2021, Alembic Pharmaceuticals, a multinational pharmaceutical company headquartered in India, bagged approval from the United States Food and Drug Administration (USFDA) for the marketing of Selexipag December 2021, Alembic Pharmaceuticals tablets. These can now be used to treat pulmonary arterial hypertension. The company’s new drug is considered to be the generic equivalent to Uptravi, the Reference Listed Drug (RLD).

Report Scope

Report Attribute	Details
Market Value in 2023	USD 7.7 Billion
Market Value in 2033	USD 12.9 Billion
Growth Rate	CAGR of 5.3% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	By drug, By diagnosis, By distribution channel, By end-user, By Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA)
Key Countries Profiled	USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, India, China, Japan, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, UAE, South Africa, Israel, GCC countries
Key Companies Profiled	Actelion Pharmaceuticals Ltd; Gilead Sciences, Inc.; Pfizer, Inc; Teva Pharmaceutical Industries Ltd; AstraZeneca plc.; Novartis AG; Merck and Co., Inc.; GlaxoSmithKline plc.; Mylan N.V; Bayer AG
Customization	Available Upon Request

Key Segments Profiled in the Eisenmenger Complex Management Industry Survey

By Drug Type:

• Antiarrhythmic Agents
• Blood Thinning Agents
• Endothelin Receptor Antagonist
• Others

By Diagnosis:

• Blood tests
• Electrocardiogram
• Chest X-ray
• Echocardiogram
• CT Scan
• MRI
• Cardiac Catheterization

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User:

• Hospitals & Clinics
• Laboratories
• Others

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Frequently Asked Questions

How is the Historical Performance of the Market?

From 2018 to 2022, the market registered a CAGR of 4.52%.

How Big will the Eisenmenger Complex Management Market by 2033?

The market is estimated to be worth USD 12.9 million by 2033.

Which Drug Type Holds Lucrative Opportunities?

Antiarrhythmic agents hold high revenue potential.

Which Countries Dominate the Global Market?

The United States, India, and China dominate the global market.

What is the Growth Forecast for the Eisenmenger Complex Management Market?

The market is forecast to register a CAGR of 5.3% through 2033.